-

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Lilium N.V. (LILM) f/k/a Qell Acquisition Corp. (QELL)

SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Lilium N.V. (NASDAQ: LILM, LILMW, QELL, QELLW) securities between March 30, 2021 and March 14, 2022, for violations of the Securities Exchange Act of 1934. Lilium purports to be a next-generation transportation company focused on developing an electric vertical take-off-and-landing ("eVTOL") aircraft for use in a new type of high-speed air transportation for people and goods.

If you would like more information about Lilium N.V.'s misconduct, click here.

What is this Case About: Lilium N.V. (LILM) f/k/a Qell Acquisition Corp. (QELL) Misled the Investing Public Regarding its Ability to Timely Launch the Lilium Jet

According to the complaint, Lilium closed its business combination with Qell Acquisition Corp. on September 14, 2021, and began trading on Nasdaq on September 15, 2021. The documents filed in support of the business combination touted the Company's technology, team, and resources, and explained that the money raised from the business combination would "be used to fund the commercial launch of Lilium's 7-Seater Jet."

However, defendants failed to disclose that Lilium had overstated the Lilium Jet's design and capabilities and its timely certification. Further, Lilium misrepresented its ability to obtain or create the necessary batteries for the Lilium Jet and failed to disclose the merger would not generate enough cash to commercially launch the Lilium Jet.

On March 14, 2022, market analyst Iceberg Research released a report entitled "LILIUM NV – THE LOSING HORSE IN THE EVTOL RACE," which detailed the current state of Lilium. Specifically, the report contends that Lilium is not on track to meet its certification timeline, the energy density of battery cells required by Lilium are currently not available commercially, and the Company only has 18 more months of cash on hand. On this news, Lilium's stock price fell 34% per share, to close at $2.44 per share on March 14, 2022.

Next Steps: If you acquired shares of Lilium N.V. (LILM) between March 30, 2021 and March 14, 2022, you have until June 17, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com

Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Lilium N.V. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:LILM

Release Summary
Lilium N.V. (LILM) f/n/a/ Qell Acquisition Corp. (QELL) Misled the Investing Public Regarding its Ability to Timely Launch the Lilium Jet
Release Versions

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Notice: Robbins LLP Informs Investors of the Atara Biotherapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026. Atara develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United Kingdom (“U.K.”). The Company’s lead product candidate is tabelecleucel (also referred to as tab-cel or EBVALLO), a T-ce...

Stockholder Notice: Robbins LLP Informs Investors of the Coty Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Coty Inc. (NYSE: COTY) common stock between November 5, 2025 and February 4, 2026. Coty together with its subsidiaries, manufactures, markets, distributes, and sells branded beauty products worldwide. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Inves...

Investor Notice: Robbins LLP Informs Investors of the Lufax Holding Ltd. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Lufax Holding Ltd. (NYSE: LU) securities between April 7, 2023 and January 26, 2025. Lufax Holding Ltd engages in the retail credit and enablement business to borrowers and institutions in China. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigat...
Back to Newsroom